Nanoparticles and target Drug delivery for cancer treatment: A Comprehensive review

  • Nandish Pathak PHIS
  • Pratim Pathak Patel Healthcare LLC

Abstract

In the healthcare industry, the biggest challenges are cancer. However, there are several drugs are available for the treatment of cancer. In these treatments cure cancer affecting the collateral toxicity to healthy cells.  In addition to the drug delivery systems in cancer have many barriers such as immune clearance or hepatic, renal. Thus, to improve treatment and overcome these problems the nanoparticle-loaded drug is one the solution. Moreover, the nanomedicine opens a new era in the healthcare industry as an effective drug delivery system.  The nanoparticle drug delivery has significant characteristics for treatments such as less toxicity, high loading capacity, and stability of the drug. This review aims to present the conventional cancer treatment and elaborate on the nanoparticle-loaded drug delivery system to overcome the side effects of the conventional treatment.

Keywords: Targeted Drug delivery systems, Nanoparticles, cancer treatment

Downloads

Download data is not yet available.

References

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017;67(3):177-93.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
3. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. Journal of controlled release: official journal of the Controlled Release Society. 2015; 200:138-57.
4. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Molecular cancer therapeutics. 2006;5(8):1909-17.
5. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annual review of biomedical engineering. 2012; 14:1-16.
6. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. Journal of controlled release: official journal of the Controlled Release Society. 2012; 161(2):505-22.
7. von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BYS. Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends in biotechnology. 2017;35(2):159-71.
8. Stylianopoulos T, Poh MZ, Insin N, Bawendi MG, Fukumura D, Munn LL, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophysical journal. 2010; 99(5):1342-9.
9. Locatelli E, Comes Franchini M. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system. Journal of Nanoparticle Research. 2012; 14(12):1-17.
10. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer research. 2016; 76(14 Supplement):2065.
11. Hawker CJ, Wooley KL. The convergence of synthetic organic and polymer chemistries. Science (New York, NY). 2005; 309(5738):1200-5.
12. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends in pharmacological sciences. 2009; 30(11):592-9.
13. Hu CM, Kaushal S, Tran Cao HS, Aryal S, Sartor M, Esener S, et al. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Molecular pharmaceutics. 2010; 7(3):914-20.
14. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: application of nanotechnology in cancer therapy. Drug discovery today. 2010; 15(19-20):842-50.
15. Shao Z, Shao J, Tan B, Guan S, Liu Z, Zhao Z, et al. Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. International journal of nanomedicine. 2015; 10:1223-33.
16. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Advanced drug delivery reviews. 2011; 63(3):170-83.
17. Menjoge AR, Kannan RM, Tomalia DA. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug discovery today. 2010; 15(5-6):171-85.
18. Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. International journal of nanomedicine. 2008; 3(3):311-21.
19. Park JH, von Maltzahn G, Ruoslahti E, Bhatia SN, Sailor MJ. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angewandte Chemie (International ed in English). 2008; 47(38):7284-8.
20. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie (International ed in English). 2014; 53(46):12320-64.
21. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Current opinion in chemical biology. 2010; 14(4):529-37.
22. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug delivery. 2015; 22(6):849-61.
23. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of Microencapsulation. 2018; 35(2):204-17.
24. Senter PD. Potent antibody drug conjugates for cancer therapy. Current opinion in chemical biology. 2009; 13(3):235-44.
25. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of Controlled Release. 2016; 226:148-67.
26. Pathak Nandish, Pratim Pathak. Applications of liposome in cancer drug delivery and treatment: A review Asian Journal of Pharmaceutical Research and Development. 2019; 7(1):62-5.
27. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science (New York, NY). 1978; 202(4374):1290-3.
28. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Advanced drug delivery reviews. 2008; 60(10):1193-208.
29. Xu J, Luft JC, Yi X, Tian S, Owens G, Wang J, et al. RNA replicon delivery via lipid-complexed PRINT protein particles. Molecular pharmaceutics. 2013; 10(9):3366-74.
30. Hoare TR, Kohane DS. Hydrogels in drug delivery: Progress and challenges. Polymer. 2008; 49(8):1993-2007.
31. Bregoli L, Movia D, Gavigan-Imedio JD, Lysaght J, Reynolds J, Prina-Mello A. Nanomedicine applied to translational oncology: A future perspective on cancer treatment. Nanomedicine : nanotechnology, biology, and medicine. 2016; 12(1):81-103.
32. Truong NP, Whittaker MR, Mak CW, Davis TP. The importance of nanoparticle shape in cancer drug delivery. Expert opinion on drug delivery. 2015; 12(1):129-42.
33. Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASA, editor. In-vitro and in-vivo tools in drug delivery research for optimum clinical outcomes. Boca Raton: CRC Press; 2018.
34. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2018; 536(1):95-107.
35. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018; 45:334-45.
36. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008; 14(5):1310-6.
37. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Therapeutic delivery. 2014; 5(9):1007-24.
38. Wang L, Shi C, Wright FA, Guo D, Wang X, Wang D, et al. Multifunctional Telodendrimer Nanocarriers Restore Synergy of Bortezomib and Doxorubicin in Ovarian Cancer Treatment. Cancer research. 2017; 77(12):3293-305.
39. García KP, Zarschler K, Barbaro L, Barreto JA, O'Malley W, Spiccia L, et al. Zwitterionic-Coated “Stealth” Nanoparticles for Biomedical Applications: Recent Advances in Countering Biomolecular Corona Formation and Uptake by the Mononuclear Phagocyte System. Small. 2014; 10(13):2516-29.
40. Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. Cancer research. 2016; 76(14 Supplement):2063.
41. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. Science (New York, NY). 2013; 339(6122):971-5.
42. Yuan H, Takeuchi E, Salant DJ. Podocyte slit-diaphragm protein nephrin is linked to the actin cytoskeleton. American journal of physiology Renal physiology. 2002; 282(4):F585-91.
43. Liu J, Yu M, Zhou C, Zheng J. Renal clearable inorganic nanoparticles: a new frontier of bionanotechnology. Materials Today. 2013; 16(12):477-86.
44. Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, et al. Paradoxical glomerular filtration of carbon nanotubes. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(27):12369-74.
45. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics. 2005; 2(1):3-14.
46. Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Advances in protein chemistry and structural biology. 2015; 98:1-55.
47. Shilo M, Sharon A, Baranes K, Motiei M, Lellouche JP, Popovtzer R. The effect of nanoparticle size on the probability to cross the blood-brain barrier: an in-vitro endothelial cell model. Journal of nanobiotechnology. 2015; 13:19.
48. Bhatt P, Narvekar P. Challenges and Strategies for Drug Transport across the Blood Brain Barrier. ARC Journal of Neuroscience. 2018; 3(3):17-21.
49. Lockman PR, Koziara JM, Mumper RJ, Allen DD. Nanoparticle surface charges alter blood-brain barrier integrity and permeability. Journal of drug targeting. 2004; 12(9-10):635-41.
50. Sharma HS, Sharma A. Neurotoxicity of engineered nanoparticles from metals. CNS & neurological disorders drug targets. 2012; 11(1):65-80.
51. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature biotechnology. 2015; 33(9):941-51.
52. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nature nanotechnology. 2012; 7(6):383-8.
Statistics
63 Views | 107 Downloads
How to Cite
Pathak, N., and P. Pathak. “Nanoparticles and Target Drug Delivery for Cancer Treatment: A Comprehensive Review”. International Journal of Drug Regulatory Affairs, Vol. 7, no. 1, Mar. 2019, pp. 53-58, doi:https://doi.org/10.22270/ijdra.v7i1.309.